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The objective of this study was to assess the effectiveness of a speciﬁc composition of a traditional herbal
preparation (DurrDerma) in adult patients with moderate to severe skin psoriasis. The preparation is a
newly developed topical combination containing plant-based extracts traditionally used in skin disease
as black cumin, olive oil, tea tree oil, cocoa butter completed by vitamin A and vitamin B12. We docu-
mented the effectiveness of the preparation in a ﬁrst case series. A total of 12 patients (8 males and 4
females, 21e86 y) with manifest and treatment-resistant psoriasis were included and treated for 12
weeks. All patients were assigned to twice-daily treatment with the DurrDerma preparation. Treatment
success as determined by the Psoriasis Area and Severity Index (PASI) score, the body surface area, and
the dermatology life index was achieved (PASI reduction of >75%) in 10 of the 12 treated patients (83%).
The remaining two patients showed a PASI reduction of 50%. In 5 of the patients PASI reduction was
achieved <12 weeks (between week 3e11). The beneﬁcial effect in responder patients might be
explained by a synergistic anti-oxidative and anti inﬂammatory activity of all components present in
DurrDerma. We conclude that the new preparation using a traditional approach seems to be a promising
complementary treatment for psoriasis.
Copyright © 2016, Center for Food and Biomolecules, National Taiwan University. Production and hosting
by Elsevier Taiwan LLC. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Psoriasis affects 2e3% of the European populations, and less
commonly other populations of other countries, i.e. Far East and
China.1,2 To date, there is no doubt that psoriasis is an immune-
mediated disorder as reﬂected by T cell hyperactivity and the pro-
duction of multiple proinﬂammatory cytokines, such as tumour
necrosis factor alpha (TNF- a) and Interleukin (IL)-2, IL-12, IL-17, IL-
22 or IL-23.3e5 Nevertheless, all available treatment options remain
largely unspeciﬁc, and many patients do not achieve the desired
outcome.6,7 Topical agents including corticosteroids, vitamin DEpidemiologie und
in Berlin, Luisenstrasse 57,
þ49 30 805 05 692.
chalsen).
for Food and Biomolecules,
molecules, National Taiwan Unive
ons.org/licenses/by-nc-nd/4.0/).analogous, Tazarotene, coal tar, and dithranol are predominantly
used for mild disease, and systemic agents including photo-
chemotherapy, methotrexate, ciclosporin, retinoids fumarates, and
biological agents are used for severe disease.8,9 None of these
treatment options has fully met the needs of affected patients.6,7
The question whether a combination therapy of biologic and sys-
temic agents may improve treatment outcome is yet unclear.6,7
Thus, there is a need for alternative and well-tolerable treatment
for psoriasis. In fact, many affected patients are using or seeking
new therapeutic options, including complementary and alternative
medicine.10e12
In this observational case series study, we documented the
effectiveness and tolerability of DurrDerma in adult patients with
active moderate to severe psoriasis vulgaris. The active ingredients
of DurrDerma are black cumin as the main component, and olive
oil, tea tree oil, cocoa butter, vitamin A and vitamin B12 as further
components.rsity. Production and hosting by Elsevier Taiwan LLC. This is an open access article
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A total of 12 unselected out-patients with moderate (n ¼ 6) to
severe (n ¼ 6) psoriasis as diagnosed by a dermatologist or expe-
rienced general practitioner and characterized by a Psoriasis Area
and Severity Index (PASI) score of 10 (Table 1) were treated with
DurrDerma. Patients had to had a disease endurance of >3 months
and at least one conventional previous treatment approach. Pa-
tients were informed about the available treatment with the
Durrderma preparation. Treatment duration was scheduled for 12
weeks and tubes of 200 g and boxes with 500 g were handed out as
anticipated for proper use during the planned 12-week treatment
period. Patients were asked to apply the cream twice daily and
hereby to cover all skin lesions with a thin layer of cream.
The preparation relates to compositions comprising black cumin
oil (>10%), olive oil (>10%), tea tree oil (<0,09%), cocoa butter (<4%),
vitamin A (<0,05%) and vitamin B12 (<0,05%). The advantage is the
innovative composition itself.
The essential oil components of black cumin oil are thymoqui-
nones which have been shown to have anti-oxidative, anti-in-
ﬂammatory, anti proliferative, anti-allergic and anti-bacterial
activities, as well as immunomodulatory and immunotherapeutic
characteristics. Olive oil contains a high concentration of poly-
phenols, in particular hydroxytyrosol. It has been shown to have
anti-oxidative, anti-inﬂammatory and anti-microbial activities. Tea
tree oil is mainly composed of various terpinens. It has anti-
oxidative and anti-inﬂammatory activities.
Cocoa butter is extracted from cocoa beans and contains various
anti-oxidants that are related to catechines and epicatechines, as
well as others that are related to procyanidines and polyphenols.
Vitamin A has anti-oxidative activity and is one of the cells
physiological anti-oxidants.
Vitamin B12 is a water-soluble vitamin with a key role in the
normal functioning of the brain and nervous system, as well as for
the formation of blood. It affects inter alia DNA synthesis and
regulation, fatty acid synthesis and energy production.
All patients were evaluated for 12 weeks and assessments of
disease activity with calculation of PASI took place at baseline and
at the time points of 2,4, 8 and 12 weeks after initialization of
treatment by the treating physician.
In addition, all patients completed a patient's questionnaire
assessing satisfaction with treatment and side effects. FurthermoreTable 1
Demographic baseline characteristics of treated patients.
Patient
(No.)
Sex Age
(year)
Weight
(kg)
Height
(cm)
Previous treatment
Topical
1 M 42 88 185 Corticostereoids
Phototherapy
2 M 32 89 180 Fumaric acid
Psorcutan ointment
Curatoderm ointment
Keto med-shampoo
3 M 34 90 180 Corticostereoids
4 F 43 52 169 Coal tar
Corticostereoids
Tea tree oil
Phototherapy
5 M 42 78 187 Corticostereoids
6 F 18 67 169 None
7 M 21 78 176 Corticostereoids
8 M 33 79 185 None
9 F 34 60 161 Corticostereoids
10 M 46 70 175 Corticostereoids
Tacalcitol
11 M 33 73 175 Corticostereoids
12 F 86 90 180 Corticosteroids
Phototherapycompliance with the recommended application was asked by
interview.Written informed consent was obtained from all patients
prior to treatment with DurrDerma. There was no selection of pa-
tients by age, gender, localization and severity of disease, or pre-
vious treatments.
3. Results
Patients were aged from 18 to 86 years and had a conﬁrmed
diagnosis of psoriasis for longer than 3 months. The majority of
patients had received previous standard topical and/or a systemic
therapy but were treatment-resistant. Only two patients had no
previous standard treatment (Table 1, nos. 6 and 8).
Initially, the vast majority of patients (n ¼ 10) showed a mild to
moderate increase of local inﬂammation with increased reddening
of the affected skin area (Table 2) for a short period of time. How-
ever, during continuous observation and under sustained treat-
ment a gradual and pronounced clinical improvement became
obvious in almost all cases within a few weeks. A PASI reduction of
>75% was observed in 10 of the 12 treated patients, in 3 patients
already before the 12-week assessment, in the other 7 patients
after 12 weeks of treatment (Table 2). The remaining two patients
showed a PASI reduction of 50%, at week 4 and 8. The treatment
effects in the early responders was maintained until the 12-week
assessment.
One of the non-responder patients (no.12) had autoimmune
thrombocytopenia which required continuous treatment with
Nplate (thrombopoietin receptor agonist). Whether Nplate would
have an impact on psoriasis treatment remains obscure.
Of note, one of the well responding patients had a treatment
course of topical tea tree oil (also an ingredient of DurrDerma)
before starting the DurrDerma application. This patient reported
that the previous use of tea tree oil alone was ineffective but
resulted in an exacerbation of the disease and discontinuation of
this treatment after two weeks.
3.1. Safety
The preparation was well tolerated. There were no relevant
adverse events. A mild exacerbation of the skin inﬂammationwas a
common initial response (2e4 days after treatment initialization)
with a subsequent consistent improvement of the disease stateAffected area Baseline PASI
scoreSystemic
Corticosteroids Scalp, abdomen, upper & lower
extremities, back, genitals
24,6
Cetrizin Scalp, abdomen, upper & lower
extremities, back
47,4
Lower extremities 8
Upper & lower extremities 7,2
Trunk, back, upper extremities 23,1
Scalp 4,4
Back, upper & lower extremities 28,1
Upper & lower extremities 21,6
Upper & lower extremities 23,2
Upper & lower extremities, genitals 19,6
Upper & lower extremities 6,6
Corticosteroids Upper & lower extremities, back 8,4
Table 2
Outcome of treated patients (Assessment at week 12).
Patient
(No.)
Treatment
(weeks)
Adverse
effects
Week 12
PASI response
rate (%)
Baseline PASI
score (absolute value)
1 12 ITE 100 24,6
2 12 ITE 90 47,4
3 3 None 90 8
4 12 ITE 100 7,2
5 10 ITE 90 23,1
6 13 None 100 4,4
7 32 ITE 90 28,1
8 12 ITE 90 21,6
9 12 ITE 90 23,2
10 4 ITE 50 19,6
11 8 ITE 100 6,6
12 11 None 50 8,4
PASI ¼ Psoriasis Area Severity Index; ITE ¼ Initially Transitory Exacerbation.
<10% ¼ grade 1 (light).
10e29% ¼ grade 2 (moderate to severe).
30e49% grade 3 (severe).
>49% ¼ grades 4e6 (very severe).
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acteristic of the preparation and the related pollution of clothes.Fig. 1. Skin status of the back of one patient before and after 12 week treatment with
the preparation.4. Discussion
This case series study was initiated to determine by a ﬁrst
documentation the effectiveness and tolerability of DurrDerma, a
traditional herbal preparation in a new speciﬁc combination for-
mula, in patients with manifest and treatment-resistant psoriasis.
Independent of previous treatment and severity of disease, 10 of
the 12 treated patients with the new herbal preparation were well
responding and 2 patients moderately responding. Most intringu-
ingly, psoriasis signs not only improved but completely dis-
appeared following treatment in 4 patients and nearly disappeared
in further 6 of the patients (Fig. 1). Thus, a clinical meaningful effect
of the preparation might be possible and should be tested and
evaluated by means of a randomized controlled clinical trial. As
treatment options in severe psoriasis are limited and the safety
proﬁle, so far, seems good, further research is warranted.
The question by which mechanisms DurrDerma works remains
speculative. However, based on the fact that psoriasis is an
immune-mediated disease,3e5 and that oxidative stress is playing a
key role in this process,13e20 it seems likely that anti-oxidative
products, such several food constituents,21,22 may have a positive
effect on psoriasis. The DurrDerma composition contains different
natural and herbal products which have potential anti-oxidative
and/or anti-inﬂammatory effects. Black cumin oil is obtained
from the seeds of Nigella Sativa and contains thymoquinones,
which have been shown to have anti-oxidative, anti-inﬂammatory,
anti proliferative, anti-allergic and anti-bacterial activities, as well
as immunomodulatory and immunotherapeutic character-
istics.23e27 Similarly, olive oil contains a high concentration of
polyphenols which have by large similar effects as thymoquinones
from Nigella Sativa.28e30
Tea tree oil is obtained from leaves of Melalenca alternifolia
which has anit-oxidative, anti-inﬂammatory, anti-bacterial, anti-
viral, and anti-fungal acivities.31e33
Cocoa butter is extracted from cocoa beans which also contain
various antioxidants, i.e. catechines, epicatechines, procyanidines,
and polyphenols.34 Vitamin B12 is involved in blood production,
DIVA synthesis and regulation.35
Thus, DurrDerma may provide a therapeutic effect that is not
based on an isolated substance, but rather on a synergisticcombination of various prophylactic, therapeutic, anti-
inﬂammatory, immunological and anti-microbial activities. The
synergistic effect is supported by the observation that one patient
(no. 4), previous to the application of the preparation in this case
observation, used tea tree oil which, however, led to continous
worsening of his psoriasis. In addition, there is empirical observa-
tion that many such affected patients appear to have used olive oil
without effect.
The question why DurrDerma initially induces a transitory
negative effect on psoriasis remains obscure. However, some
topical drugs, such as coal tar and anthralin have been described
also to cause a ﬂare-up (Koebner phenomenon) in patients with
active psoriasis.36,37 We do not know if the initial (mild) aggrava-
tion is a precondition for the retarded and lasting treatment effect.
Of note, patients need to be informed about this treatment kinetic
to ensure compliance. Clearly, the safety of the preparation needs to
be assessed in larger studies. However, on the background of cur-
rent existing preclinical and botanical research data of the com-
ponents of the preparation, no speciﬁc safety concerns are
expected.
A. Michalsen et al. / Journal of Traditional and Complementary Medicine 6 (2016) 395e3983985. Conclusion
In conclusion, the observations in this case series study point to
a promising and clinically relevant beneﬁcial effect of the Durr-
Derma preparation in patients with skin psoriasis. Further clinical
trials are warranted.
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